Cargando…
Selection analyses of paired HIV-1 gag and gp41 sequences obtained before and after antiretroviral therapy
Most HIV-1-infected individuals with virological failure on a pharmacologically-boosted protease inhibitor (PI) regimen do not develop PI-resistance protease mutations. One proposed explanation is that HIV-1 gag or gp41 cytoplasmic domain mutations might also reduce PI susceptibility. In a recent st...
Autores principales: | Tzou, Philip L., Rhee, Soo-Yon, Pond, Sergei L. Kosakovsky, Manasa, Justen, Shafer, Robert W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6057438/ https://www.ncbi.nlm.nih.gov/pubmed/30040081 http://dx.doi.org/10.1038/sdata.2018.147 |
Ejemplares similares
-
Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017) -
HIV-1 Group M Capsid Amino Acid Variability: Implications for Sequence Quality Control of Genotypic Resistance Testing
por: Tao, Kaiming, et al.
Publicado: (2023) -
Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons
por: Tzou, Philip L., et al.
Publicado: (2022) -
Geographically-stratified HIV-1 group M pol subtype and circulating recombinant form sequences
por: Rhee, Soo-Yon, et al.
Publicado: (2018) -
Susceptibility of SARS-CoV-2 Omicron Variants to Therapeutic Monoclonal Antibodies: Systematic Review and Meta-analysis
por: Tao, Kaiming, et al.
Publicado: (2022)